An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject
A Phase 2a Study of BMS-790052 and BMS-650032 in Combination Therapy With Japanese Subjects With Genotype 1 Chronic Hepatitis C (HCV) Virus Infection
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Hiroshima
-
Hiroshima City, Hiroshima, Japan, 734-0037
- Local Institution
-
-
Hokkaido
-
Sapporo-Shi, Hokkaido, Japan, 060-0033
- Local Institution
-
-
Kanagawa
-
Kawasaki-Shi, Kanagawa, Japan, 2138587
- Local Institution
-
-
Tokyo
-
Minato-Ku, Tokyo, Japan, 105-0001
- Local Institution
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects chronically infected with HCV Genotype 1
- HCV RNA viral load of ≥ 10*5* IU/mL (100,000 IU/mL) at screening
Exclusion Criteria:
- Subjects with evidence of liver cirrhosis
- Evidence of HCC
- Co-infection with hepatitis B virus, HIV
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: BMS-790052 + BMS-650032
|
Tablets, Oral, 60 mg, daily, 24 weeks
Tablets, Oral, 1200 mg, daily, 24 weeks
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part 1: To assess safety and tolerability based on 4 weeks safety data, as measured by related serious adverse events (SAEs) and discontinuations due to related AEs
Time Frame: Week 4
|
Week 4
|
|
Part 2: To determine the proportion of subjects who achieve SVR12 (i.e., HCV RNA < 15 IU/mL at follow-up Week 12)
Time Frame: Post-treatment Week 12
|
Post-treatment Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The safety of co-administration of BMS-790052 + BMS-650032 as measured by the frequency of SAEs, discontinuations due to AEs, and Grade 3 - 4 laboratory abnormalities
Time Frame: Weeks 4, 12, end of treatment and post-treatment Week 24
|
Weeks 4, 12, end of treatment and post-treatment Week 24
|
|
The proportion of subjects who achieve RVR (defined as HCV RNA < 15 IU/mL
Time Frame: Week 4
|
Week 4
|
|
The proportion of subjects with extended rapid virologic response (eRVR), defined as HCV RNA < 15 IU/mL
Time Frame: at both Weeks 4 and 12
|
at both Weeks 4 and 12
|
|
The proportion of subjects who achieve SVR24 (defined as HCV RNA < 15 IU/mL
Time Frame: at follow-up Week 24
|
at follow-up Week 24
|
|
Resistant variants associated with clinical failure
Time Frame: Weeks 4, 12, end of treatment and post-treatment Week 24
|
Weeks 4, 12, end of treatment and post-treatment Week 24
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Kao JH, Jensen DM, Manns MP, Jacobson I, Kumada H, Toyota J, Heo J, Yoffe B, Sievert W, Bessone F, Peng CY, Roberts SK, Lee YJ, Bhore R, Mendez P, Hughes E, Noviello S. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int. 2016 Jul;36(7):954-62. doi: 10.1111/liv.13049. Epub 2016 Jan 24.
- Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, McPhee F, Hughes E, Kumada H. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013 Apr;58(4):655-62. doi: 10.1016/j.jhep.2012.09.037. Epub 2012 Nov 23.
- Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013 Apr;58(4):646-54. doi: 10.1016/j.jhep.2012.11.012. Epub 2012 Nov 22.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- RNA Virus Infections
- Virus Diseases
- Blood-Borne Infections
- Disease Attributes
- Liver Diseases
- Flaviviridae Infections
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Infections
- Communicable Diseases
- Hepatitis
- Hepatitis A
- Hepatitis C
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Asunaprevir
Other Study ID Numbers
Other Study ID Numbers
- AI447-017
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.